About Amylyx Pharmaceuticals, Inc.
https://amylyx.comAmylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.
CEO
Joshua B. Cohen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 127
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citigroup
Buy
B of A Securities
Buy
Goldman Sachs
Buy
Guggenheim
Buy
Baird
Outperform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
FMR LLC
Shares:11.38M
Value:$160.11M
PERCEPTIVE ADVISORS LLC
Shares:8.95M
Value:$125.96M
BLACKROCK, INC.
Shares:7.14M
Value:$100.47M
Summary
Showing Top 3 of 181
About Amylyx Pharmaceuticals, Inc.
https://amylyx.comAmylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $16.17M ▼ | $-34.39M ▲ | 0% | $-0.37 ▲ | $-34.27M ▲ |
| Q2-2025 | $0 | $42.72M ▲ | $-41.44M ▼ | 0% | $-0.46 ▼ | $-41.3M ▼ |
| Q1-2025 | $0 ▲ | $37.8M ▼ | $-35.91M ▲ | 0% ▼ | $-0.42 ▲ | $-37.65M ▲ |
| Q4-2024 | $-665K ▼ | $39.99M ▼ | $-37.55M ▲ | 5.65K% ▲ | $-0.55 ▲ | $-40.49M ▲ |
| Q3-2024 | $416K | $75.27M | $-72.7M | -17.48K% | $-1.07 | $-75.44M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $343.99M ▲ | $362.74M ▲ | $30.75M ▲ | $332M ▲ |
| Q2-2025 | $180.83M ▼ | $194.6M ▼ | $26.72M ▲ | $167.88M ▼ |
| Q1-2025 | $204.07M ▲ | $219.68M ▲ | $18.26M ▼ | $201.42M ▲ |
| Q4-2024 | $176.5M ▼ | $193.63M ▼ | $28.87M ▼ | $164.76M ▼ |
| Q3-2024 | $234.4M | $250.71M | $54.51M | $196.2M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-34.39M ▲ | $-30.37M ▼ | $5.24M ▼ | $191.61M ▲ | $167.09M ▲ | $-30.39M ▼ |
| Q2-2025 | $-41.44M ▼ | $-25.25M ▲ | $22.99M ▲ | $-31K ▼ | $-1.68M ▲ | $-25.27M ▲ |
| Q1-2025 | $-35.91M ▲ | $-39.82M ▲ | $-43.66M ▼ | $65.66M ▲ | $-17.62M ▼ | $-39.84M ▲ |
| Q4-2024 | $-37.55M ▲ | $-59.01M ▼ | $64.98M ▲ | $110K ▲ | $5.56M ▲ | $-59.03M ▼ |
| Q3-2024 | $-72.7M | $-41.57M | $38.82M | $80K | $-2.44M | $-41.55M |
CEO
Joshua B. Cohen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 127
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citigroup
Buy
B of A Securities
Buy
Goldman Sachs
Buy
Guggenheim
Buy
Baird
Outperform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
FMR LLC
Shares:11.38M
Value:$160.11M
PERCEPTIVE ADVISORS LLC
Shares:8.95M
Value:$125.96M
BLACKROCK, INC.
Shares:7.14M
Value:$100.47M
Summary
Showing Top 3 of 181